Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is advancing its clinical development of fibroblast-based therapies, showing promising preclinical results in improving wound healing for diabetic foot ulcers, particularly through enhanced re-epithelialization and increased cell proliferation in healed tissue. The company has also reported successful pre-IND animal trials demonstrating reduced tumor sizes following the transplantation of bone marrow organoids, indicating a scalable solution for cancer treatment after cryopreservation. Recent updates on positive IND-enabling progress for both fibroblast spheroid utilization in chronic-relapse psoriasis and enhancements in the bone marrow organoid platform further underscore FibroBiologics's potential in addressing significant unmet medical needs within chronic disease management.

Bears say

FibroBiologics Inc faces significant risks impacting its financial outlook, primarily related to the potential failure of its developmental candidates to meet peak commercial revenue estimates, which could be influenced by factors such as market size and penetration rates. Additionally, the company may struggle to secure the necessary capital resources to fund its operations, which is critical for sustaining development and commercialization efforts. The uncertainty surrounding these issues raises concerns about the company’s ability to effectively execute its business strategy and achieve financial viability.

Fibrobiologics Inc (FBLG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.